NYSE · EBS

Emergent Biosolutions, Inc.

$7.26 -$0.24 (-3.20%) 1D After hours

Key Metrics

$386.97M
Market cap
P/E · TTM
$676.80M
Revenue · TTM
−$8.60M
Net income
EPS · TTM $-0.15
Dividend yield
Free cash flow $135.40M
Beta · 1Y 1.26
EBITDA · TTM $97.40M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 24
    From its Jan 29 high, the share price fell 39%.

    Peak close $11.90 on Jan 29; trough close $7.26 on Jul 24. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -39%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Mar 2
    The stock moved +10.3% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 2
  • Feb 27
    The stock moved -26.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 27

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$386.97M
Enterprise value$800.27M
Shares outstanding51.6M
52-wk range$5.62 – $14.06
Avg volume · 20D1.4M
Net cash −$413.30M
Book value / share$9.13
IndustryPharmaceutical Preparations
ExchangeNYSE
About Emergent Biosolutions, Inc.
IPO dateNov 15, 2006
Employees900

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S0.57
P/FCF2.86
EV/EBITDA8.22
EV/Sales1.18
Graham №

Profitability

Gross
Operating 0.5%
Net -1.3%
FCF 20.0%
ROE / ROIC -1.7% · -0.9%

Financial Health

Current ratio4.29
Quick ratio2.08
Debt / equity1.10
Debt / EBITDA 5.89
Net cash −$413.30M
Working capital$488.90M

Cash Flow · TTM

Operating CF $148.00M
Capex −$12.60M
Free cash flow $135.40M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

6 / 9
Middling fundamentals · 6 of 9 signals passing

Altman Z-Score

1.1
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings